Pathological and biochemical outcomes after radical prostatectomy in men with low‐risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria

• DOI: 10.1111/j.1464-410x.2012.11658.x
• Publication Date: 2013-01-15T15:10:47Z
• Authors: Koji Mitsuzuka; Shintaro Narita; Takuya Koie; Yasuhiro Kaiho; Norihiko Tsuchiya; Takahiro Yoneyama; Narihiko Kakoi; Sadafumi Kawamura; Tatsuo Tochigi; Tomonori Habuchi; Chikara Ohyama; Yoichi Arai
• Keywords: Watchful waiting

What's known on the subject? and What does study add? Active surveillance has been widely accepted as a treatment tool for low‐risk prostate cancer, use of Prostate Cancer Research International: Surveillance ( PRIAS ) criteria can select smaller less aggressive tumours in disease. The shows pathological outcomes radical prostatectomy patients with disease who met criteria. It found that ∼20% had unfavourable features only 30% satisfied insignificant cancer p T 2 stage, G leason score ≤6 tumour volume <2.5 mL. concludes close follow‐up including repeat biopsy or MRI is necessary to minimize unexpected progression Objective To assess effectiveness International identifying indolent cancer. Patients Methods Data from 1268 undergoing without neoadjuvant therapy were retrospectively reviewed. Within this cohort, n = 211) classified according whether they (Group A , 87) did not meet B 124) Pathological upstaging, upgrading, 5‐year prostate‐specific antigen PSA recurrence‐free survival compared between two groups, factors predicted upgrading recurrence analysed by univariate multivariate methods. Results 3 stage was present 10.3% Group 18.5% P 0.08). Gleason 4+3 greater seen 19.5% 29.9% 0.01). mean (range) 0.81 (0.03–5.09) mL 1.40 (0.04–8.21) < rates total mL, 30.6% 15.4% 0.07). With median 44 months, 91.2% 86.4% 0.47). In analysis, density independent upstaging. Conclusions Although could more favourable even about one five men three ten Close careful avoid misclassification disease, especially during first few years active surveillance.